Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
07 févr. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 janv. 2023 08h05 HE
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
04 janv. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces Pricing of Public Offering
08 déc. 2022 21h04 HE
|
Replimune Group Inc
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces Proposed Public Offering
07 déc. 2022 16h04 HE
|
Replimune Group Inc
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
07 déc. 2022 07h00 HE
|
Replimune Group Inc
RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%,...
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
07 déc. 2022 06h30 HE
|
Replimune Group Inc
RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma...
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
23 nov. 2022 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune to Host Virtual Investor Event on December 7, 2022
22 nov. 2022 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...